Background and Objectives: Adequate supplies of donor blood remains a major challenge in sub-Saharan Africa. This is exacerbated by lack of confirmatory testing for transfusion transmitted infections by Blood Transfusion Services (BTS) leading to significant blood disposal owing to putatively high seroprevalence rates amongst Ugandan blood donors. We aimed to ascertain the false discovery rate of the Architect anti-HCV screening assay, categorise screen-reactive samples into 3 groups: presumed false-positive, active and past infection, and develop an algorithm for confirmatory testing. Materials and Methods: 470 screen-reactive HCV blood donations were re-tested using the Architect anti-HCV assay, an alternative antibody test (SD biosensor)...
Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti...
Background: The prevalence of blood screening assays for hepatitis C infection among blood donors re...
A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodefi...
International audienceBackground: False positivity in blood screening may cause unnecessary deferral...
Four screening strategies (no testing, HC Abbott, HC Pasteur, and a combined test) for the detection...
INTRODUCTION: Hepatitis C virus (HCV) antibody seroprevalence studies overestimate the true infectio...
Objective: We aimed at the determination of “False Positive” testing percentage for the TTIs (Transf...
BACKGROUND: The World Health Organization recommends universal and quality-controlled screening of b...
Objective: The objective of this study is to evaluate the prevalence of anti-hepatitis C virus antib...
In low-income-countries, screening for hepatitis C virus (HCV) infection is often based on rapid tes...
International audienceIntroduction: A lack of access to hepatitis C virus (HCV) diagnostics is a sig...
International audienceFour screening strategies (no testing, HC Abbott, HC Pasteur, and a combined t...
The relative contribution of serologic screening and nucleic acid testing (NAT) to prevent hepatitis...
Background: Transfusion of blood and its components save life, but may transmit infectious disease w...
Abstract. The aim of this study was to determine the prevalence of HCV infection and the signal/cuto...
Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti...
Background: The prevalence of blood screening assays for hepatitis C infection among blood donors re...
A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodefi...
International audienceBackground: False positivity in blood screening may cause unnecessary deferral...
Four screening strategies (no testing, HC Abbott, HC Pasteur, and a combined test) for the detection...
INTRODUCTION: Hepatitis C virus (HCV) antibody seroprevalence studies overestimate the true infectio...
Objective: We aimed at the determination of “False Positive” testing percentage for the TTIs (Transf...
BACKGROUND: The World Health Organization recommends universal and quality-controlled screening of b...
Objective: The objective of this study is to evaluate the prevalence of anti-hepatitis C virus antib...
In low-income-countries, screening for hepatitis C virus (HCV) infection is often based on rapid tes...
International audienceIntroduction: A lack of access to hepatitis C virus (HCV) diagnostics is a sig...
International audienceFour screening strategies (no testing, HC Abbott, HC Pasteur, and a combined t...
The relative contribution of serologic screening and nucleic acid testing (NAT) to prevent hepatitis...
Background: Transfusion of blood and its components save life, but may transmit infectious disease w...
Abstract. The aim of this study was to determine the prevalence of HCV infection and the signal/cuto...
Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti...
Background: The prevalence of blood screening assays for hepatitis C infection among blood donors re...
A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodefi...